Janwillem Naesens, MSc, MBA
Janwillem Naesens is Managing Partner of Droia Oncology ventures, a specialist investor in early-stage oncology drug development companies. Prior to joining Droia in 2013, Mr. Naesens was Investment Manager at Waterland Private Equity, a European investment group providing growth capital to small and mid-sized companies. Mr. Naesens started his career at McKinsey & Company in New York, working as a strategy consultant in life sciences and finance.
At Droia, Mr. Naesens focuses on early-stage investments and company creations. He currently serves on the board of directors of Bioncotech Therapeutics, Octimet Oncology, Convert Pharmaceuticals, Cristal Therapeutics, Normoxys and Black Belt Therapeutics. Mr. Naesens is also board observer at PACT Pharmaceuticals, and was formerly board member of Tusk Therapeutics (acquired by Roche). Mr. Naesens holds a MSc in Engineering from the University of Leuven and an MBA from INSEAD, Fontainebleau.